Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Elena Verzoni; Giacomo Cartenì; Enrico Cortesi; Diana Giannarelli; Andrea De Giglio; Roberto Sabbatini; Sebastiano Buti; Sabrina Rossetti; Francesco Cognetti; Francesca Rastelli; Alberto Sobrero; Daniele Turci; Cora N. Sternberg; Camillo Porta; Federico Cappuzzo; Giampaolo Tortora; Davide Tassinari; Stefano Panni; Antonio Pazzola; Gianmarco Surico; Alessandra Raimondi; Ugo De Giorgi; Giuseppe Procopio; on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group

doi:10.1186/s40425-019-0579-z

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

XML

Research Article

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password